Motzer md is a medical oncologist at memorial sloan kettering cancer center.
Mskcc renal cell carcinoma risk stratification.
Motzer s research focuses on renal cell carcinoma germ cell tumors and bone marrow and blood cell.
He received the career development award from the national institutes of health and the schonfeld award from the kidney cancer association.
This health tool determines survival in the case of patient with metastatic renal cell carcinoma based on their clinical and laboratory data.
It is based on the 670 patient original 1999 study by robert j motzer md at the memorial sloan kettering cancer center mskcc and is the most widely recognized prognostic algorithm for rcc.
The two scores of 5 respectively 7 items are the only clinical judgment tools that address survival of patients with metastatic renal cell carcinoma.
The renal cell carcinoma tool consists of the motzer score resulted from the memorial sloan kettering cancer center mskcc study and the extended version created by mekhail.
This nomogram was designed to be used by physicians and people with renal cell carcinoma.
Who can use this tool.
Our kidney cancer nomogram is a prediction tool designed to help patients and their physicians calculate the likely outcome of their surgical treatment for newly diagnosed renal cell carcinoma a type of kidney cancer.